X0306 4 2017-07-05 0 0001420565 AILERON THERAPEUTICS INC ALRN 0001656151 Shanafelt Armen C/O LILLY VENTURES 115 WEST WASHINTON ST. SUITE 1680-SOUTH INDIANAPOLIS IN 46204 1 0 0 0 Common Stock 2017-07-05 4 C 0 844987 A 844987 I See Footnote Common Stock 2017-07-05 4 P 0 250000 15.00 A 1094987 I See Footnote Series D Preferred Stock 2017-07-05 4 C 0 3390885 0.00 D Common Stock 341238 0 I See Footnote Series E-2 Preferred Stock 2017-07-05 4 C 0 1907373 0.00 D Common Stock 191946 0 I See Footnote Series E-3 Preferred Stock 2017-07-05 4 C 0 1654411 0.00 D Common Stock 166489 0 I See Footnote Series F Preferred Stock 2017-07-05 4 C 0 1443972 0.00 D Common Stock 145312 0 I See Footnote The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. These shares are held directly by Lilly Ventures Fund I LLC, or LVFI. LV Management Group, LLC, or LVMG, is the management company for LVFI and as such may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which includes the Reporting Person. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his proportionate pecuniary interest therein. Exhibit Index: 24.1 Power of Attorney /s/ Kira A. Nelson, Kira A. Nelson as attorney-in-fact for Armen B. Shanafelt 2017-07-07